Ventyx Biosciences (NASDAQ:VTYX) Price Target Raised to $14.00

Ventyx Biosciences (NASDAQ:VTYX) had its price objective boosted by research analysts at Wells Fargo & Company from $11.00 to $14.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 59.64% from the stock’s previous close.

A number of other equities analysts have also recently commented on the company. Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday. Finally, Oppenheimer raised their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Stock Performance

Shares of Ventyx Biosciences stock traded down $0.49 on Friday, reaching $8.77. 2,638,338 shares of the stock were exchanged, compared to its average volume of 2,134,669. The firm has a market cap of $625.39 million, a PE ratio of -5.22 and a beta of 1.23. The firm’s 50 day moving average is $4.08 and its 200-day moving average is $2.85. Ventyx Biosciences has a one year low of $0.78 and a one year high of $9.50.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. On average, equities research analysts expect that Ventyx Biosciences will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Ventyx Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC acquired a new stake in Ventyx Biosciences during the second quarter worth approximately $9,707,000. Marshall Wace LLP acquired a new stake in shares of Ventyx Biosciences during the 2nd quarter worth approximately $5,129,000. Redmile Group LLC increased its stake in shares of Ventyx Biosciences by 1,164.1% in the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock valued at $1,805,000 after acquiring an additional 1,445,615 shares in the last quarter. Monaco Asset Management SAM lifted its position in shares of Ventyx Biosciences by 372.7% during the 1st quarter. Monaco Asset Management SAM now owns 1,134,444 shares of the company’s stock valued at $1,305,000 after acquiring an additional 894,444 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Ventyx Biosciences by 925.6% during the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after acquiring an additional 794,401 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.